These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 1790421)

  • 1. Screening for vertebral osteoporosis using individual risk factors. The Multicentre Vertebral Fracture Study Group.
    Cooper C; Shah S; Hand DJ; Adams J; Compston J; Davie M; Woolf A
    Osteoporos Int; 1991 Oct; 2(1):48-53. PubMed ID: 1790421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteoporosis prevalence and levels of treatment in primary care: the Australian BoneCare Study.
    Eisman J; Clapham S; Kehoe L;
    J Bone Miner Res; 2004 Dec; 19(12):1969-75. PubMed ID: 15537439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vertebral fracture prevalence among women screened for the Fracture Intervention Trial and a simple clinical tool to screen for undiagnosed vertebral fractures. Fracture Intervention Trial Research Group.
    Vogt TM; Ross PD; Palermo L; Musliner T; Genant HK; Black D; Thompson DE
    Mayo Clin Proc; 2000 Sep; 75(9):888-96. PubMed ID: 10994823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vertebral fracture in postmenopausal Chinese women: a population-based study.
    Cui L; Chen L; Xia W; Jiang Y; Cui L; Huang W; Wang W; Wang X; Pei Y; Zheng X; Wang Q; Ning Z; Li M; Wang O; Xing X; Lin Q; Yu W; Weng X; Xu L; Cummings SR
    Osteoporos Int; 2017 Sep; 28(9):2583-2590. PubMed ID: 28560474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study.
    McCloskey E; Selby P; Davies M; Robinson J; Francis RM; Adams J; Kayan K; Beneton M; Jalava T; Pylkkänen L; Kenraali J; Aropuu S; Kanis JA
    J Bone Miner Res; 2004 May; 19(5):728-36. PubMed ID: 15068495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. When should the doctor order a spine X-ray? Identifying vertebral fractures for osteoporosis care: results from the European Prospective Osteoporosis Study (EPOS).
    Kaptoge S; Armbrecht G; Felsenberg D; Lunt M; O'Neill TW; Silman AJ; Reeve J;
    J Bone Miner Res; 2004 Dec; 19(12):1982-93. PubMed ID: 15537441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and older.
    Seeman E; Vellas B; Benhamou C; Aquino JP; Semler J; Kaufman JM; Hoszowski K; Varela AR; Fiore C; Brixen K; Reginster JY; Boonen S
    J Bone Miner Res; 2006 Jul; 21(7):1113-20. PubMed ID: 16813532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis.
    Marcus R; Wang O; Satterwhite J; Mitlak B
    J Bone Miner Res; 2003 Jan; 18(1):18-23. PubMed ID: 12510801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The impact of subclinical vertebral fractures on health-related quality of life in women with osteoporosis].
    Alekna V; Tamulaitiene M; Būtenaite V
    Medicina (Kaunas); 2006; 42(9):744-50. PubMed ID: 17028473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women.
    Kanis JA; Borgstrom F; Johnell O; Jonsson B
    Osteoporos Int; 2004 Nov; 15(11):862-71. PubMed ID: 15175846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors.
    Roux C; Reginster JY; Fechtenbaum J; Kolta S; Sawicki A; Tulassay Z; Luisetto G; Padrino JM; Doyle D; Prince R; Fardellone P; Sorensen OH; Meunier PJ
    J Bone Miner Res; 2006 Apr; 21(4):536-42. PubMed ID: 16598373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.
    Miller PD; Hattersley G; Riis BJ; Williams GC; Lau E; Russo LA; Alexandersen P; Zerbini CA; Hu MY; Harris AG; Fitzpatrick LA; Cosman F; Christiansen C;
    JAMA; 2016 Aug; 316(7):722-33. PubMed ID: 27533157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal progression of fracture prevalence through a population of postmenopausal women with osteoporosis.
    Lindsay R; Pack S; Li Z
    Osteoporos Int; 2005 Mar; 16(3):306-12. PubMed ID: 15455193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validity and reliability of the Italian version of the ECOS-16 questionnaire in postmenopausal women with prevalent vertebral fractures due to osteoporosis.
    Salaffi F; Malavolta N; Cimmino MA; Di Matteo L; Scendoni P; Carotti M; Stancati A; Mulé R; Frigato M; Gutierrez M; Grassi W;
    Clin Exp Rheumatol; 2007; 25(3):390-403. PubMed ID: 17631735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Geography of Fracture Incidence in Postmenopausal Women with Osteoporosis Treated with Abaloparatide.
    McClung MR; Williams GC; Hattersley G; Fitzpatrick LA; Wang Y; Miller PD
    Calcif Tissue Int; 2018 Jun; 102(6):627-633. PubMed ID: 29285549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial.
    Ensrud KE; Black DM; Palermo L; Bauer DC; Barrett-Connor E; Quandt SA; Thompson DE; Karpf DB
    Arch Intern Med; 1997 Dec 8-22; 157(22):2617-24. PubMed ID: 9531231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk.
    Boonen S; Adachi JD; Man Z; Cummings SR; Lippuner K; Törring O; Gallagher JC; Farrerons J; Wang A; Franchimont N; San Martin J; Grauer A; McClung M
    J Clin Endocrinol Metab; 2011 Jun; 96(6):1727-36. PubMed ID: 21411557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors associated with incident clinical vertebral and nonvertebral fractures in postmenopausal women: the Canadian Multicentre Osteoporosis Study (CaMos).
    Papaioannou A; Joseph L; Ioannidis G; Berger C; Anastassiades T; Brown JP; Hanley DA; Hopman W; Josse RG; Kirkland S; Murray TM; Olszynski WP; Pickard L; Prior JC; Siminoski K; Adachi JD
    Osteoporos Int; 2005 May; 16(5):568-78. PubMed ID: 15517191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of prevalent vertebral fractures, bone density, and alendronate treatment with incident vertebral fractures: effect of number and spinal location of fractures. The Fracture Intervention Trial Research Group.
    Nevitt MC; Ross PD; Palermo L; Musliner T; Genant HK; Thompson DE
    Bone; 1999 Nov; 25(5):613-9. PubMed ID: 10574584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The population-based prevalence of osteoporotic vertebral fracture and densitometric osteoporosis in postmenopausal women over 50 in Valencia, Spain (the FRAVO study).
    Sanfélix-Genovés J; Reig-Molla B; Sanfélix-Gimeno G; Peiró S; Graells-Ferrer M; Vega-Martínez M; Giner V
    Bone; 2010 Sep; 47(3):610-6. PubMed ID: 20601286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.